Hypertension treatment in patients with sleep apnea from the European Sleep Apnea Database (ESADA) cohort - towards precision medicine.
Sven SvedmyrJan HednerMaria Rosaria BonsignoreCarolina LombardiGianfranco ParatiOndrej LudkaDing ZouLudger Grotenull nullPublished in: Journal of sleep research (2022)
We recruited 5,970 patients with hypertension with obstructive sleep apnea (OSA) on current antihypertensive treatment from the European Sleep Apnea Database (ESADA) cohort. The group was subdivided into those receiving monotherapy (n = 3,594) and those receiving dual combined therapy (n = 2,376). We studied how major OSA confounders like age, gender, and body mass index as well as the degree of sleep apnea modified office systolic and diastolic blood pressure. Beta-blockers alone or in combination with a diuretic were compared with other antihypertensive drug classes. Monotherapy with beta-blocker was associated with lower systolic blood pressure, particularly in non-obese middle-aged males with hypertension. Conversely, the combination of a beta-blocker and a diuretic was associated with lower systolic and diastolic blood pressure in patients with hypertension with moderate-severe OSA. Systolic blood pressure was better controlled in female patients using this combined treatment. Our cross-sectional data suggest that specific clinical characteristics and type of antihypertensive medication influence the degree of blood pressure control in patients with hypertension with OSA. Controlled trials are warranted.
Keyphrases
- blood pressure
- sleep apnea
- obstructive sleep apnea
- positive airway pressure
- hypertensive patients
- heart rate
- body mass index
- combination therapy
- cross sectional
- middle aged
- end stage renal disease
- adverse drug
- newly diagnosed
- healthcare
- left ventricular
- chronic kidney disease
- type diabetes
- stem cells
- mental health
- clinical trial
- angiotensin converting enzyme
- prognostic factors
- bone marrow
- deep learning
- emergency department
- artificial intelligence
- study protocol
- atrial fibrillation
- insulin resistance